Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

PHASE4RecruitingINTERVENTIONAL
Enrollment

10,742

Participants

Timeline

Start Date

October 18, 2024

Primary Completion Date

January 1, 2029

Study Completion Date

February 1, 2030

Conditions
Hypertensive Disorders of PregnancyPreeclampsiaGestational Hypertension
Interventions
DRUG

Aspirin 81 mg

Participants will be assigned to 81mg Aspirin

DRUG

Aspirin 162 mg

Participants will be assigned to 162mg Aspirin

Trial Locations (12)

10032

RECRUITING

Columbia University, New York

15213

RECRUITING

University of Pittsburg Magee, Pittsburgh

23501

RECRUITING

Eastern Virginia Medical School - Old Dominion University, Norfolk

27514

RECRUITING

University of North Carolina, Chapel Hill, Chapel Hill

27710

RECRUITING

University of New Mexico, Albuquerque

39216

RECRUITING

University of Mississippi, Jackson

43210

RECRUITING

The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine, Columbus

60611

RECRUITING

Northwestern University, Chicago

77030

RECRUITING

University of Texas, Houston, Houston

90048

RECRUITING

Cedars Sinai Medical Center, Los Angeles

94158

RECRUITING

University of California, San Francisco, San Francisco

02905

RECRUITING

Brown University, Providence

All Listed Sponsors
collaborator

Patient-Centered Outcomes Research Institute

OTHER

collaborator

Northwestern University

OTHER

collaborator

Preeclampsia Foundation

OTHER

lead

Ohio State University

OTHER

NCT06468202 - Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL | Biotech Hunter | Biotech Hunter